earance (results were,
respectively, 17 percent, 53 percent, 63 percent, 77 percent, 53
percent, vs. 0 percent of those receiving placebo; p<0.001 for
all groups except the single-dose group, 200mg at week 0).
The most common adverse events observed were injection site
reactions, nasopharyngitis (inflammation of the nose and pharynx),
upper respiratory infections and headache.
"We're very excited about these promising Phase II results,"
said Eugene Sun, M.D., vice president, Global Pharmaceutical
Clinical Development at Abbott. "In all but one of the dosing
groups in this study, at least 90 percent of patients showed
significant improvement, and many experienced almost complete
clearance. We look forward to studying ABT-874 further."
Abbott's Commitment to Immunology
Abbott is focused on the discovery and development of innovative
treatments for immunologic diseases. The Abbott Bioresearch Center,
founded in 1989 in Worcester, Mass., United States, is a
world-class discovery and basic research facility supporting
research and development of biologic treatments. Abbott
Biotechnology Limited, which opened earlier this year in
Barceloneta, Puerto Rico, United States, is the main production
facility for Abbott's anti-TNF treatment and one of the world's
largest centers for production of monoclonal antibodies.
About Abbott
Abbott is a global, broad-based health care company devoted to
the discovery, development, manufacture and marketing of
pharmaceuticals and medical products, including nutritionals,
devices and diagnostics. The company employs 65,000 people and
markets its products in more than 130 countries.
Abbott's news releases and other information are available on
the company's Web site at http://www.abbott.com.
CONTACT: U.S. Media, Liz Shea, +1-847-935-2211, or International
Media,Tracy Sorrentino, +1-847-937-8712, or Financial, John
Thomas,+1-847-938-26
'"/>
Page: 1 2 3 4 Related medicine technology :1.
Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work
Productivity in Patients with Rheumatoid Arthritis2.
New Analysis of Data Shows Treatment With Abbotts Humira
(Adalimumab) Significantly Reduced Disease-Related Hospitalization
for Patients with Crohns Disease3.
Abbotts Xience V Everolimus Eluting Coronary Stent Superior to
Taxus Stent in Spirit III U.S. Pivotal Clinical Trial4.
Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis5.
An Investigational Study Released at ADA Showed that Initial
Combination Therapy with Januvia (sitagliptin) and Metformin Led to
Improvement in Markers of Beta Cell Function in Patients with Type
2 Diabetes6.
Late Breaking Data Released at ADA Showed that the Investigational
Use of Januvia and Metformin as Initial Combination Therapy
Provided Significant Glucose Lowering Efficacy over 54 Weeks in
Patients with Type 2 Diabetes7.
Investigational Study Demonstrated a Re-Establishment of Clinical
Improvement with Orencia (Abatacept) in Children with Juvenile
Idiopathic Arthritis upon Re-Introduction of Therapy8.
Mercks Investigational Migraine Treatment MK-0974 Significantly
Improved Migraine Pain on Several Efficacy Measures in a Phase II
Study9.
Data Demonstrated Metastatic Melanoma Response to Investigational
Immunotherapy Ipilimumab10.
Investigational Drug Cediranib (AZD2171) Shows Promise in Patients
With Recurrent Glioblastoma (GBM)11.
Additional New Data from Satraplatin SPARC Phase 3 Investigational
Trial Presented at ASCO Annual Meeting